Related Experiment Video
Updated: Sep 28, 2025
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
'Personalizing' shorter regimens: Need of the hour
Kranti Garg1, Komaldeep Kaur1, Aditi Gupta1
1Department of Pulmonary Medicine, Government Medical College, Patiala, Punjab, India.
Introduction:
The launch of injectable shorter regimens under Programmatic Management of Drug Resistant Tuberculosis (PMDT) guidelines 2017 under Revised National Tuberculosis Control Program (RNTCP) was a welcome step as it decreased the duration of treatment significantly in Drug Resistant Tuberculosis (DRTB) patients. The objective of the present study was to evaluate the treatment outcomes of patients started on injectable shorter regimens from March 2018 to May, 2019.
Methods:
Retrospective study which scrutinized medical records of 85 patients started on injectable shorter regimen was conducted. Necessary information on possible patient and disease related predicting factors like age, gender, weight, HIV status, presence of diabetes mellitus (DM), anemia, gap between diagnosis and initiation of treatment, duration of intensive phase (IP) and time of sputum conversion was retrieved, and analyzed for possible association with treatment outcomes.
Results:
56.5% had successful treatment outcomes. Age, gender, BMI, diabetic/anemic status and gap between diagnosis and initiation of treatment had no statistically significant relationship with the final outcomes. Duration of IP, sputum conversion and time of outcome during the course of illness emerged as significant factors in successful outcomes.
Conclusion:
The injectable shorter regimens were suitable for a variety of population irrespective of demographic disparities. Patients need to be followed closely as microbiological parameters serve as early indicators of unsuccessful outcomes. These regimens can serve as an alternate choice in patients not tolerating the all oral shorter Bedaquiline containing shorter regimen. Similar such options with combinations of different drugs for individualizing treatment regimens is the need of the hour.
Insights
Injectable shorter regimens for drug-resistant tuberculosis (DR-TB) showed a 56.5% success rate. Microbiological improvements, like sputum conversion, are key indicators for successful treatment outcomes in DR-TB patients.
Area of Science:
- Medicine
- Infectious Diseases
- Public Health
Background:
- The implementation of injectable shorter regimens for Programmatic Management of Drug-Resistant Tuberculosis (PMDT) in 2017 aimed to reduce treatment duration for Drug-Resistant Tuberculosis (DRTB) patients.
- This approach was a significant advancement under the Revised National Tuberculosis Control Program (RNTCP).
Purpose of the Study:
- To evaluate the treatment outcomes of patients initiated on injectable shorter regimens between March 2018 and May 2019.
- To identify factors associated with successful treatment outcomes in DR-TB patients receiving these regimens.
Main Methods:
- A retrospective study analyzing medical records of 85 patients on injectable shorter regimens.
- Data collected included patient demographics (age, gender, weight, HIV status), comorbidities (diabetes mellitus, anemia), treatment initiation gap, intensive phase duration, and sputum conversion time.
Main Results:
- Overall successful treatment outcome was observed in 56.5% of patients.
- Demographic factors and comorbidities like diabetes mellitus and anemia were not significantly associated with treatment success.
- Duration of the intensive phase, time to sputum conversion, and timing of outcome were significant predictors of successful treatment.
Conclusions:
- Injectable shorter regimens are effective across diverse patient populations, regardless of demographic differences.
- Close patient monitoring is crucial, with microbiological parameters like sputum conversion serving as early indicators of treatment success or failure.
- These regimens offer a viable alternative for patients unable to tolerate all-oral shorter regimens, such as those containing Bedaquiline.
Related Concept Videos
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
01:15Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
01:28Drug Therapy
Antianxiety Medications
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...